Department of Radiation Oncology, Taichung Veterans General Hospital, Taichung, Taiwan.
Division of Radiation Physics, Department of Radiation Oncology, Taichung Veterans General Hospital, Taichung, Taiwan.
Breast. 2024 Dec;78:103796. doi: 10.1016/j.breast.2024.103796. Epub 2024 Sep 4.
We compared the dosimetric characteristics of the target and organs at risk (OARs) as well as the preliminary clinical outcomes between two accelerated partial breast irradiation (APBI) techniques.
Forty-four patients diagnosed with left-sided early breast cancer who underwent APBI using either interstitial brachytherapy (IB) or stereotactic body radiation therapy (SBRT) with CyberKnife (CK) were retrospectively reviewed. The dosimetric parameters of the target and OARs were compared. Preliminary clinical outcomes, including tumor control and acute toxicity, were analyzed.
Treatment plans with CK demonstrated a better cardiac dose-sparing effect. Radiation doses to the heart at V for the CK and IB groups were 24.4 % and 60.4 %, respectively (p < 0.001), while the mean heart doses for the CK and IB groups were 107.4 cGy and 204 cGy, respectively (p < 0.001). The heart D and the ipsilateral lung received a lower dose in the IB group, without any significant differences. The median follow-up time in the CK and IB groups was 28.6 and 61.3 months, respectively. No patients died from either breast cancer or cardiac events during follow-up. A locoregional recurrence event at the neck occurred in one patient within the IB group.
APBI planned by CK was shown to have a better dose-sparing effect on the heart, as well as better conformity and homogeneity to the target. CK is a non-invasive treatment which showed minimal acute toxicity and promising tumor control.
我们比较了两种加速部分乳腺照射(APBI)技术的靶区和危及器官(OAR)的剂量学特征以及初步的临床结果。
回顾性分析了 44 例左侧早期乳腺癌患者,分别采用间质内近距离放疗(IB)或立体定向体部放射治疗(SBRT)联合 CyberKnife(CK)进行 APBI。比较了靶区和 OAR 的剂量学参数。分析了初步的临床结果,包括肿瘤控制和急性毒性。
CK 治疗计划显示出更好的心脏剂量保护作用。CK 和 IB 组的心脏 V 剂量分别为 24.4%和 60.4%(p<0.001),而 CK 和 IB 组的平均心脏剂量分别为 107.4 cGy 和 204 cGy(p<0.001)。IB 组心脏 D 和同侧肺接受的剂量较低,但无显著差异。CK 和 IB 组的中位随访时间分别为 28.6 个月和 61.3 个月。随访期间,无患者死于乳腺癌或心脏事件。在 IB 组,有 1 例患者出现颈部局部复发。
CK 计划的 APBI 对心脏具有更好的剂量保护作用,同时对靶区具有更好的适形性和均匀性。CK 是一种非侵入性治疗方法,具有最小的急性毒性和有前途的肿瘤控制。